|
Euro Resist Wk: Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) (oral slides)
|
|
|
Reported by Jules Levin
13th European HIV & Hepatitis Workshop; June 3-5, 2015; Barcelona, Spain
MR Underwood1, F DeAnda1, D Dorey2, K Hightower1, R Wang1, S Griffith1, J Horton3
1 GlaxoSmithKline, North Carolina, USA, 2 GlaxoSmithKline, Mississauga, ON, Canada. 3 Currently PAREXEL International (previously GlaxoSmithKline, North Carolina, USA.)
![HCV1.gif](../images/061715/061715-6/HCV1.gif)
![HCV2.gif](../images/061715/061715-6/HCV2.gif)
![HCV3.gif](../images/061715/061715-6/HCV3.gif)
![HCV4.gif](../images/061715/061715-6/HCV4.gif)
![HCV5.gif](../images/061715/061715-6/HCV5.gif)
![HCV6.gif](../images/061715/061715-6/HCV6.gif)
![HCV7.gif](../images/061715/061715-6/HCV7.gif)
![HCV8.gif](../images/061715/061715-6/HCV8.gif)
![HCV9.gif](../images/061715/061715-6/HCV9.gif)
|
|
|
|
|
|
|